KEI Comments on NIH Exclusive License to Australian firm SubRed

On Monday April 26, 2021, Knowledge Ecology International submitted comments regarding the “Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype” (86 FR 18545) by the… Continue Reading


Zolgensma is a gene therapy for spinal muscular atrophy (SMA) that was approved by the US FDA in May 2019, at a price of $2.1 million per patient. Zolgensma was licensed from a children’s hospital where it was developed on… Continue Reading